CAREDX, INC.

Public Equity (NASDAQ)BiotechnologyPrecision MedicineTransplant Diagnostics

📍 Brisbane, California, United States• Founded 1998• 763 employees

StreetZero Signal 67

Be the first to signal interest

About CAREDX, INC.

CareDx, Inc. (Nasdaq: CDNA) is a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. The company provides non-invasive molecular testing solutions including AlloSure Kidney, AlloMap Heart, AlloSure Heart, and AlloSure Lung. It is headquartered in Brisbane, California, and went public via IPO in 2014.

LATEST FUNDINGRule 144

$6.8M

Announced 2026-11-05

TOTAL RAISED$138M

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for CAREDX, INC..

Create free account Sign in

Free plan includes 3 full deal profiles every month.

IN THE NEWS

EMPLOYEES763

FOUNDED1998

HQBrisbane, California, United States

Industry

Public Equity (NASDAQ)

Investors

Integral Capital Partners Intel

Key highlights

Public company on NASDAQ (CDNA) since 2014 IPO.
Specializes in non-invasive testing for heart, kidney, and lung transplant patients.
Reported Q1 2026 revenue of $118 million, up 39% year-over-year.
Maintains an active equity incentive plan for employee RSU grants.
Total historical funding of $138M across 18 rounds with 26 institutional investors.